

Figure 3 PRP survival curves from Phase I (top panel) and Phase II (bottom panel). Phase I results showed no significant difference in survival time before requiring PRP between conventional diabetes management (control, $n=8$) and patients treated with maximally tolerated doses of octreotide (OCT, 600-3000 $\mu\text{g}/\text{day}$, $n=8$). Phase II results showed highly significant differences for survival of individual eyes to laser treatment for control, ($n=22$) and octreotide + thyroxine treatment (OCT+T₄, $n=24$).

OIPE
SEP 25 2003
PATENT & TRADE





Figure 3 PRP survival curves from Phase I (top panel) and Phase II (bottom panel). Phase I results showed no significant difference in survival time before requiring PRP between conventional diabetes management (control, n=8) and patients treated with maximally tolerated doses of octreotide (OCT, 600-3000 µg/day, n=8). Phase II results showed highly significant differences for survival of individual eyes to laser treatment for control, (n=22) and octreotide + thyroxine treatment (OCT+T₄, n=24).